The DOI matches its Crossref record; 509 of the 513 references it cites were found in a registry or an index; 127 of the 249 sources its claims cite were checked for support.
Drug repurposing for cancer therapy
Open accessAbstract
Comprehensive review of methods and candidate repurposed drugs for cancer therapy.
Overview
CoChat Summary
## TL;DR
This is a narrative review of drug repurposing for cancer therapy, summarizing experimental and computational strategies, hallmark-targeting examples, tumor microenvironment targets, and nanomaterial-based delivery. It argues that repurposed drugs may speed development and reduce cost, but clinical translation remains limited by bioavailability, dosing, toxicity, and regulatory barriers.
## Key findings
- The review organizes drug repurposing around the 14 hallmarks of cancer and the tumor microenvironment (TME), and notes that repurposed drugs may target multiple malignancy features and support combination therapy.
- It states that conventional drug development can take 10–15 years and cost $1–2 billion, whereas repurposing is faster and cheaper because existing drugs already have known safety, dosage, and toxicity profiles.
- The paper highlights several reported quantitative findings from prior studies, including a 45% risk reduction in thyroid cancer among metformin users in Eastern countries, and lower gynecological cancer occurrence with metformin: HR = 0.60 (95% CI: 0.49–0.74), endometrial cancer HR = 0.65 (95% CI: 0.50–0.85), and ovarian cancer HR = 0.47 (95% CI: 0.27–0.82).
- It also cites a phase I clinical trial of leflunomide in refractory multiple myeloma where disease stabilization occurred in 9 of 11 patients.
## Methods
- Design: Narrative review/systematic overview of published work on drug repurposing for cancer therapy, centered on hallmarks of cancer, TME-targeting therapy, and nanomaterial-based delivery.
- Data/sample: The text does not report a primary study sample; instead, it synthesizes examples from preclinical studies, epidemiological analyses, and clinical trials, and mentions use of databases and tables of repurposed-drug candidates.
- Main analysis: The paper categorizes repurposing strategies into experimental approaches (including phenotypic screening and organoid/tumoroid models) and computational approaches (including molecular docking, network analysis, data mining, similarity analysis, machine learning, and transcriptional signature methods).
## Limitations
- The paper explicitly states that many repurposed drugs have not yet translated into clinical application, and that clinical trial evidence is limited for several TME-targeting candidates.
- It notes several practical barriers: bioavailability limits, instability, poor solubility, toxicity, dosing uncertainty, patent/IP issues, regulatory barriers, and limited funding for trials.
- The text also makes evident, but does not present as a formal limitation, that much of the evidence discussed is preclinical and often based on small or ongoing clinical studies rather than large randomized trials.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
99 Valid · 15 Not valid · 82 Not checked · 27 Own results and interpretations
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“Furthermore, TPL has been shown to induce autophagy-mediated caspase-independent cell death in tumor cells.”
§ Drug repurposing for cancer therapy > Drug repurposing: candidates for the therapeutic targeting of hallmarks of cancer > Inducing cell death
What the sources say
- Disputedcites [91] Zhao, F. et al. Triptolide induces protective autophagy through activation of the CaMKKβ-AMPK signaling pathway in prostate cancer cells. Oncotarget 7, 5366–5382 (2016). sourceExperimental — accuracy not yet measured
The Results section (‘Triptolide induces cytoprotective autophagy in PCa cells’; page not supplied) concludes that autophagy protects prostate cancer cells from triptolide-induced death: inhibiting autophagy increased both cell death and caspase-3 cleavage. This is contrary to the attributed claim that triptolide-induced autophagy mediates caspase-independent cell death. (LLM, conf=0.90)
Checked by a reasoning model — may be wrong.
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“Celecoxib has been shown to enhance the efficacy of BRAF/MEKi treatments in melanoma through suppression of the NF-κB pathway.”
§ Drug repurposing for cancer therapy > Drug repurposing: candidates for the therapeutic targeting of hallmarks of cancer > Targeting tumor-promoting inflammation
What the sources say
- Disputedcites [183] Vergani, E. et al. miR-146a-5p impairs melanoma resistance to kinase inhibitors by targeting COX2 and regulating NFkB-mediated inflammatory mediators. Cell Commun. Signal 18, 156 (2020). sourceExperimental — accuracy not yet measured
The Results section (“Targeting COX2 restores melanoma sensitivity to BRAF/MEKi”; page unavailable) supports increased growth inhibition and cytotoxicity with celecoxib plus BRAF/MEKi in melanoma cells. But it reports noncanonical NF-κB activation, not suppression, and attributes the enhanced apoptotic effects to reduced PGE2 production. The Discussion likewise describes activation of NF-κB signaling cascades during celecoxib-induced cell death. (LLM, conf=0.88)
Checked by a reasoning model — may be wrong.
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“Dong and colleagues reported the nuanced relationship between EGCG and the WNT/β-catenin signaling pathway by demonstrating that overexpression of β-catenin could either augment or reduce the anticancer effects of EGCG.147”
§ Drug repurposing for cancer therapy > Drug repurposing: candidates for the therapeutic targeting of hallmarks of cancer > Interfering with replication
What the sources say
- Disputedcites [147] Dong, C. et al. Epigallocatechin-3-gallate suppresses the growth of human osteosarcoma by inhibiting the Wnt/β-catenin signalling pathway. Bioengineered 13, 8490–8502 (2022). sourceExperimental — accuracy not yet measured
In “EGCG inhibits OS growth by regulating the Wnt/β-catenin pathway” (Figure 4c–f; page not supplied), the paper reports that β-catenin overexpression inhibited EGCG’s antitumour and pro-apoptotic effects. It was β-catenin knockdown, not overexpression, that strengthened those effects. (LLM, conf=0.91)
Checked by a reasoning model — may be wrong.
hedgedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“Another extensive meta-analysis ascertained a notably lower gynecological cancer occurrence in those undergoing metformin treatment compared to alternative therapies (gynecological cancer: HR = 0.60, 95% CI: 0.49–0.74; endometrial cancer: HR = 0.65, 95% CI: 0.50–0.85; ovarian cancer: HR = 0.47, 95% CI: 0.27–0.82).203”
§ Drug repurposing for cancer therapy > Drug repurposing: candidates for the therapeutic targeting of hallmarks of cancer > Locking phenotypic plasticity
What the sources say
- Disputedcites [203] Yao, K., Zheng, H. & Li, T. Association between metformin use and the risk, prognosis of gynecologic cancer. Front. Oncol. 12, 942380 (2022). sourceExperimental — accuracy not yet measured
The Discussion section on cancer risk (page not provided) reports no significant association between metformin use and the occurrence of gynecological, endometrial, or ovarian cancer in women with diabetes. The cited hazard ratios appear instead in the Discussion section on prognosis, where they describe overall survival among patients with cancer, not cancer occurrence. (LLM, conf=0.90)
Checked by a reasoning model — may be wrong.
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Notably, high-throughput screening using sophisticated models can identify compounds that mitigate disease symptoms without necessitating pre-existing knowledge about the drug-target interactions.29,30”
§ Drug repurposing for cancer therapy > Drug repurposing strategies
What the sources say
- Partly supportedcites [29] Huang, H., Zhang, P., Qu, X. A., Sanseau, P. & Yang, L. Systematic prediction of drug combinations based on clinical side-effects. Sci. Rep. 4, 7160 (2014). sourceExperimental — accuracy not yet measured
The Abstract (page unavailable) describes a computational model that uses clinical side effects to predict drug combinations, rather than requiring drug-target interaction data. But it does not show that the predicted compounds mitigate disease symptoms; the Discussion (page unavailable) says the predictions need experimental testing. The Abstract also distinguishes this approach from high-throughput screening, which it says is impractical for all possible combinations. (LLM, conf=0.86)
- Could not verifycites [30] Kuhn, M., Campillos, M., Letunic, I., Jensen, L. J. & Bork, P. A side effect resource to capture phenotypic effects of drugs. Mol. Syst. Biol. 6, 343 (2010). sourceExperimental — accuracy not yet measured
The Introduction (page unavailable) discusses databases of cellular phenotypes and the potential of large-scale computational methods; it does not describe screening sophisticated models to find compounds that relieve disease symptoms. Searches for high-throughput screening, symptom mitigation, and drug-target-independent screening found no passage addressing that claim. (LLM, conf=0.73)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
113 more claims · 51 with their cited sources checked
Create a free account to see all 223 claims and to verify the 13 references still open.
- It may state two separate claims as one. 87
- Probably not a substantial claim. 25
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Self-check results appear here once an independent check has confirmed them.
Cited works that were retracted
Works this paper cites that were later retracted, from the retraction notices publishers deposit. Major when the notice came out before this paper was published.
A note, not an issue: for example, a cited work that was retracted only after this paper was published, which its authors could not have known.
In the paper
“134 Ongoing clinical trials are currently examining the ef fi cacy of simvastatin against various cancers, including breast (NCT00807950, NCT05550415), gastric (NCT01099085, NCT03086291), colorectal (NCT01238094), and bladder (NCT02360618) cancer.”
Cited work 10.1038/cddis.2017.46 · retracted 2025-11-27 · notice 10.1038/s41419-025-08275-8 · this paper published 2024-04-19
Citations
Cites
1 retracted
Li, J., Liu, J., Liang, Z., He, F., Yang, L., Li, P., Jiang, Y., Wang, B., Zhou, C., Wang, Y., et al. (2017) · Cell Death & Disease · doi:10.1038/cddis.2017.46 · Cited by 43 · cited 1×
“134 Ongoing clinical trials are currently examining the ef fi cacy of simvastatin against various cancers, including breast (NCT00807950, NCT05550415), gastric (NCT01099085, NCT03086291), colorectal (NCT01238094), and bladder (NCT02360618) cancer.”
BackgroundRetractedHallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590 · cited 3×
“…is activated in response to numerous DNA damage events including germline or somatic defects in DNA repair, 166 oncogene-induced replication stress, 69 fl awed mitotic chromosome segregation, 167 clashes between replication and transcription machinery 168 or even as a consequence of genotoxic…”
BackgroundInfluentialGene Ontology: tool for the unification of biology
Ashburner, M., Ball, C. A., Blake, J. A., Botstein, D., Butler, H., Cherry, J. M., Davis, A. P., Dolinski, K., Dwight, S. S., Eppig, J. T., et al. (2000) · Nature Genetics · doi:10.1038/75556 · Cited by 43,206
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Tissue-based map of the human proteome
Uhlén, M., Fagerberg, L., Hallström, B. M., Lindskog, C., Oksvold, P., Mardinoglu, A., Sivertsson, Å., Kampf, C., Sjöstedt, E., Asplund, A., et al. (2015) · Science · doi:10.1126/science.1260419 · Cited by 15,286
STRING v10: protein–protein interaction networks, integrated over the tree of life
Szklarczyk, D., Franceschini, A., Wyder, S., Forslund, K., Heller, D., Huerta-Cepas, J., Simonovic, M., Roth, A., Santos, A., Tsafou, K. P., et al. (2015) · Nucleic Acids Research · doi:10.1093/nar/gku1003 · Cited by 10,436
The Human Genome Browser at UCSC
Kent, W. J., Sugnet, C. W., Furey, T. S., Roskin, K. M., Pringle, T. H., Zahler, A. M., & Haussler, A. D. (2002) · Genome Research · doi:10.1101/gr.229102 · Cited by 10,400
Hallmarks of Cancer: New Dimensions
Hanahan, D. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-1059 · Cited by 9,887 · cited 2×
“Furthermore, standardization of speci fi c tumoroid culture conditions is essential for enhancing 67,68 Understanding these hallmarks is pivotal for developing effective strategies for cancer prevention, diagnosis, and treatment.”
BackgroundKEGG: new perspectives on genomes, pathways, diseases and drugs
Kanehisa, M., Furumichi, M., Tanabe, M., Sato, Y., & Morishima, K. (2017) · Nucleic Acids Research · doi:10.1093/nar/gkw1092 · Cited by 8,865
DrugBank 5.0: a major update to the DrugBank database for 2018
Wishart, D. S., Feunang, Y. D., Guo, A. C., Lo, E. J., Marcu, A., Grant, J. R., Sajed, T., Johnson, D., Li, C., Sayeeda, Z., et al. (2018) · Nucleic Acids Research · doi:10.1093/nar/gkx1037 · Cited by 8,404
Cited by
Glaviano, A., Lau, H., Carter, L. M., Lee, E. H. C., Lam, H. Y., Okina, E., Tan, D. J. J., Tan, W., Ang, H. L., Carbone, D., et al. (2025) · Journal of Hematology & Oncology · doi:10.1186/s13045-024-01634-6 · Cited by 181
Applications of Artificial Intelligence in Drug Repurposing
Wan, Z., Sun, X., Li, Y., Chu, T., Hao, X., Cao, Y., & Zhang, P. (2025) · Advanced Science · doi:10.1002/advs.202411325 · Cited by 126
A review of the current trends in computational approaches in drug design and metabolism
Ouma, R. B. O., Ngari, S. M., & Kibet, J. K. (2024) · Discover Public Health · doi:10.1186/s12982-024-00229-3 · Cited by 95
“Similarly, bufulfone and chlorambucil which were initially developed as alkylating agents based on toxic chemical warfare agent mustard gas, have been repurposed for treating leukemia [55].”
Artificial Intelligence in Head and Neck Cancer: Innovations, Applications, and Future Directions
Pham, T. D., Teh, M., Chatzopoulou, D., Holmes, S., & Coulthard, P. (2024) · Current Oncology · doi:10.3390/curroncol31090389 · Cited by 88
“For instance, drugs initially developed for other cancers or diseases may exhibit potential efficacy against HNC, offering a faster and more cost-effective route to developing new treatments [156,157].”
BackgroundAn Open Access Database of Licensed Cancer Drugs
Pantziarka, P., Capistrano, R., Potter, A. D., Vandeborne, L., & Bouche, G. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.627574 · Cited by 65
Metadata
- Authors
- Xia, Y., Sun, M., Huang, H., & Jin, W.-L.
- Affiliations
- Johns Hopkins University (US)
- Guiyang Medical University (CN)
- Corresponding author
- Huang, Hai
- Venue
- Signal Transduction and Targeted Therapy
- Published
- 2024-04-19
- Volume
- 9
- Issue
- 1
- Pages
- 92-92
- ISSN
- 2059-3635 (ISSN-L)
- PMC
- PMC11026526
- OpenAlex
- W4394934376
- Cited by
- 443
- References
- 513
- Citations by year
- 2026: 168 · 2025: 214 · 2024: 60
- FWCI
- 12.35
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Signal Transduction and Targeted Therapy (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- National Natural Science Foundation of China (82060442)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Mechanisms and Therapy
- Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
- Keywords
- drug repurposing, cancer therapy, cancer hallmarks, tumor microenvironment, drug resistance, combination therapy, nanotechnology, topical drug delivery, anticancer agents, clinical translation
- MeSH terms
- Combined Modality Therapy, Humans, Neoplasms, Drug Delivery Systems, Treatment Outcome, Drug Repositioning, Tumor Microenvironment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Drug repurposing for cancer therapy. https://app.cochat.ai/papers/10.1038/s41392-024-01808-1
- The paper
- Xia, Y., Sun, M., Huang, H., & Jin, W.-L. (2024). Drug repurposing for cancer therapy. Signal Transduction and Targeted Therapy. https://doi.org/10.1038/s41392-024-01808-1
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.